POLARGO Trial: Polatuzumab Vedotin Improves Survival in Relapsed/Refractory DLBCL
40% reduction in death risk with Pola-R-GemOx vs R-GemOx alone in relapsed/refractory DLBCL (HR 0.60, P=.0017) – POLARGO trial results.
POLARGO Trial: Polatuzumab Vedotin Improves Survival in Relapsed/Refractory DLBCL Read More ยป